News
Tiotropium via Respimat didn’t raise COPD mortality risk
Major finding: Patients with chronic obstructive pulmonary were at no increased risk of death if they used 2.5 or 5 mcg tiotropium delivered by...
The FDA is expected to make a decision on approval by Sept. 21. The agency usually follows the recommendations of its advisory panels. Panel members had no relevant conflicts of interest to disclose.
The TIOSPIR study was published in October 2013 (N. Engl. J. Med. 2013;369:1491-501).